Anthropic's S-1 Drags Circular AI Economics Into Public Disclosure

Anthropic filed a public Form S-1 with the SEC today (file no.

What happened

333-299633), planning a Nasdaq listing under ticker "ANT." Verified numbers, cross-checked against the filing via Fortune, CNBC's reading, euronews, and multiple independent trackers: revenue $16.29B for H1 2026 (vs $1.16B a year earlier — up ~1,300%); FY2025 revenue $4.59B; net loss $80.7B for H1 — but $72.4B of that is a non-cash fair-value charge on convertible notes/derivatives/SAFEs triggered by Anthropic's own rising valuation. The real operating loss was $693M (down from $2.14B a year earlier), and Q2 revenue hit $11.6B with a claimed 8% operating margin. 80% of revenue is consumption-based (per-token), 20% subscriptions. 5,300 employees. Pricing/size are blank; WSJ sources say a listing the week of Nov 16, possibly raising ~$100B at a $1.5–2T valuation — unconfirmed by Anthropic. The sleeper number: roughly $417B in new compute obligations signed this year, plus an estimated $125–150B more for 2028–2031 capacity.

The caveats that matter

Aggregators repeated the "$80.7B loss — one of the largest ever recorded" framing without the fair-value footnote in headlines; the operating-loss figure is what actually matters. The $1.5–2T valuation and Nov 16 date are single-outlet (WSJ) — treat as expectation, not fact.

What it means

The S-1 converts private-market circularity (Nvidia→OpenAI→cloud→back) into public-market disclosure, with all its uncomfortable questions written down in a document underwriters must price. Note the strategic contrast with OpenAI: no ad tier, no sponsored answers anywhere in the filing — Anthropic is explicitly positioning "enterprise/API, no ads" as the differentiator, right as OpenAI ships its agent-for-work models (below). The $417B compute commitments are the real story for anyone modeling AI economics: that's a decade-scale fixed-cost base that requires revenue to keep doubling. A public Anthropic also creates the first honest comp for the whole sector — if ANT trades at $1.5T+ on $32B run-rate revenue, every private lab reprices; if it stumbles, the paper valuations get questioned loudly.